{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T11:51:24Z","timestamp":1791460284933,"version":"4.3.4"},"reference-count":40,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2025,10,1]]},"abstract":"<jats:sec>\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Fumarate hydratase\u2013deficient renal cell carcinoma (FH-deficient RCC) is a lethal kidney cancer that has limited therapeutic options.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the efficacy and safety of sintilimab plus axitinib for treatment of advanced FH-deficient RCC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This phase 2 multicenter, open-label, single-arm nonrandomized clinical trial enrolled patients with pathologically confirmed, treatment-naive, advanced FH-deficient RCC and an Eastern Cooperative Oncology Group Performance Status of 0 to 2 from July 1, 2021, to August 29, 2023, across 8 institutions in China. The data cutoff date was December 1, 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Intervention<\/jats:title>\n                    <jats:p>Patients received sintilimab, 200 mg, intravenously every 3 weeks, combined with axitinib, 5 mg, orally twice daily, until disease progression, intolerable toxic effects, or withdrawal of consent.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>The primary end points were objective response rate (ORR) via Response Evaluation Criteria in Solid Tumors, version 1.1, and progression-free survival (PFS). Secondary end points included safety, overall survival, disease control rate (proportion of patients with complete or partial response or stable disease for \u22656 months), duration of response, and exploratory genomic-associated outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 52 patients screened for eligibility, 41 patients (median [range] age, 36 [18-75] years; 10 [24%] female) were enrolled. The median (range) duration of follow-up was 26.0 (0.7-41.6) months. Overall, ORR was 56% (23 patients; 95% CI, 40%-72%), with a median duration of response of not reached (NR; 95% CI, 23.3 months to NR). The disease control rate was 73% (30 patients). The median PFS was 19.8 months (95% CI, 10.9 months to NR). Patients with low somatic copy number alteration burden showed more favorable therapeutic outcomes. Thirteen patients (32%) experienced grade 3 or higher treatment-related adverse events, with the most frequent being hypertriglyceridemia in 3 (7%), rash in 2 (5%), and anemia in 2 (5%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>In this nonrandomized clinical trial, the combination of sintilimab and axitinib demonstrated encouraging ORR and PFS with manageable safety profile in patients with FH-deficient RCC. This combination therapy warrants further validation in a randomized clinical trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov Identifier:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT04387500\">NCT04387500<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaoncol.2025.2497","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T15:31:00Z","timestamp":1755185460000},"page":"1169","source":"Crossref","is-referenced-by-count":9,"title":["Sintilimab Plus Axitinib for Advanced Fumarate Hydratase\u2013Deficient Renal Cell Carcinoma"],"prefix":"10.1001","volume":"11","author":[{"given":"Xingming","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Urology, Institute of Urology, Sichuan Clinical Research Center for Kidney and Urologic Diseases, West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Urology, Sichuan Clinical Research Center for Kidney and Urologic Diseases, West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayu","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Urology, Sichuan Clinical Research Center for Kidney and Urologic Diseases, West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Urology, Sichuan Clinical Research Center for Kidney and Urologic Diseases, West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongquan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Urology, Southwest Hospital, Army Medical University, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuntian","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Radiology, West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deying","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Clinical Research Management, West China Hospital, Sichuan University, Chengdu, China"},{"name":"Chinese Evidence-Based Medicine Center, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Clinical Research Management, West China Hospital, Sichuan University, Chengdu, China"},{"name":"Chinese Evidence-Based Medicine Center, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaowen","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, West China Second University Hospital, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxue","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Pathology, West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhao","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Urology, Sichuan Clinical Research Center for Kidney and Urologic Diseases, West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zilin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Urology, Sichuan Clinical Research Center for Kidney and Urologic Diseases, West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinan","family":"Sheng","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital and Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kan","family":"Gong","sequence":"additional","affiliation":[{"name":"Department of Urology, Peking University First Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Liu","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Kunming Medical University, Kunming, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhibin","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Urology, The First People\u2019s Hospital of Neijiang, Neijiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxing","family":"Qiu","sequence":"additional","affiliation":[{"name":"Department of Urology, Sichuan Provincial People\u2019s Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongping","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Urology, Zhejiang Cancer Hospital, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangheng","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Urology, Guizhou Provincial People\u2019s Hospital, Guiyang, China"},{"name":"Guizhou University School of Medicine, Guiyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Urology, The General Hospital of Western Theater Command, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanshan","family":"Yang","sequence":"additional","affiliation":[{"name":"Research Institute, GloriousMed Clinical Laboratory, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuyi","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Pathology, West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Nie","sequence":"additional","affiliation":[{"name":"Department of Pathology, West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengni","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pathology, West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junru","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Urology, Sichuan Clinical Research Center for Kidney and Urologic Diseases, West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinge","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Urology, Sichuan Clinical Research Center for Kidney and Urologic Diseases, West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Urology, Sichuan Clinical Research Center for Kidney and Urologic Diseases, West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijing","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Urology, Sichuan Clinical Research Center for Kidney and Urologic Diseases, West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Urology, Sichuan Clinical Research Center for Kidney and Urologic Diseases, West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jindong","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Urology, Sichuan Clinical Research Center for Kidney and Urologic Diseases, West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haolin","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Urology, Sichuan Clinical Research Center for Kidney and Urologic Diseases, West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchao","family":"Ni","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Urology, Sichuan Clinical Research Center for Kidney and Urologic Diseases, West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Urology, Sichuan Clinical Research Center for Kidney and Urologic Diseases, West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Urology, Sichuan Clinical Research Center for Kidney and Urologic Diseases, West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiying","family":"He","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Urology, Sichuan Clinical Research Center for Kidney and Urologic Diseases, West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Biotherapy, West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Urology, Sichuan Clinical Research Center for Kidney and Urologic Diseases, West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ni","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pathology, West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhua","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Urology, Sichuan Clinical Research Center for Kidney and Urologic Diseases, West China Hospital, Sichuan University, Chengdu, China"},{"name":"Department of Urology, West China Tianfu Hospital, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangxi","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Urology, Sichuan Clinical Research Center for Kidney and Urologic Diseases, West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Radiology, West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Urology, Institute of Urology, Sichuan Clinical Research Center for Kidney and Urologic Diseases, West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"coi250042r1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.molmed.2016.12.001","article-title":"Fumarates and cancer.","volume":"23","author":"Fuhler","year":"2017","journal-title":"Trends Mol Med"},{"issue":"5","key":"coi250042r2","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.eururo.2022.06.016","article-title":"The 2022 World Health Organization classification of tumours of the urinary system and male genital organs\u2014part a: renal, penile, and testicular tumours.","volume":"82","author":"Moch","year":"2022","journal-title":"Eur Urol"},{"issue":"21","key":"coi250042r3","doi-asserted-by":"publisher","first-page":"4807","DOI":"10.1158\/1078-0432.CCR-22-1279","article-title":"Genomic characteristics and single-cell profiles after immunotherapy in fumarate hydratase-deficient renal cell carcinoma.","volume":"28","author":"Dong","year":"2022","journal-title":"Clin Cancer Res"},{"key":"coi250042r4","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ejca.2021.04.009","article-title":"Response to systemic therapy in fumarate hydratase-deficient renal cell carcinoma.","volume":"151","author":"Carril-Ajuria","year":"2021","journal-title":"Eur J Cancer"},{"issue":"10","key":"coi250042r5","doi-asserted-by":"publisher","first-page":"2910","DOI":"10.1158\/1078-0432.CCR-20-4367","article-title":"Comprehensive molecular characterization and response to therapy in fumarate hydratase-deficient renal cell carcinoma.","volume":"27","author":"Gleeson","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"2","key":"coi250042r6","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.eururo.2022.05.029","article-title":"Genomic profiling and response to immune checkpoint inhibition plus tyrosine kinase inhibition in FH-deficient renal cell carcinoma.","volume":"83","author":"Xu","year":"2023","journal-title":"Eur Urol"},{"issue":"1","key":"coi250042r7","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13073-023-01182-7","article-title":"Genomic and transcriptomic features between primary and paired metastatic fumarate hydratase-deficient renal cell carcinoma.","volume":"15","author":"Liang","year":"2023","journal-title":"Genome Med"},{"issue":"6","key":"coi250042r8","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1158\/1078-0432.CCR-20-3788","article-title":"Integrated molecular characterization of fumarate hydratase-deficient renal cell carcinoma.","volume":"27","author":"Sun","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"15","key":"coi250042r9","doi-asserted-by":"publisher","first-page":"5004","DOI":"10.1200\/JCO.2020.38.15_suppl.5004","article-title":"Results from a phase II study of bevacizumab and erlotinib in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell cancer.","volume":"38","author":"Srinivasan","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"coi250042r10","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12943-019-0974-6","article-title":"Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment.","volume":"18","author":"Yi","year":"2019","journal-title":"Mol Cancer"},{"issue":"11","key":"coi250042r11","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1200\/JCO.23.01569","article-title":"Lenvatinib plus pembrolizumab versus sunitinib in first-line treatment of advanced renal cell carcinoma: final prespecified overall survival analysis of CLEAR, a phase III study.","volume":"42","author":"Motzer","year":"2024","journal-title":"J Clin Oncol"},{"issue":"2","key":"coi250042r12","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100450","article-title":"Efficacy and safety of avelumab plus axitinib in elderly patients with advanced renal cell carcinoma: extended follow-up results from JAVELIN Renal 101.","volume":"7","author":"Tomita","year":"2022","journal-title":"ESMO Open"},{"issue":"9","key":"coi250042r13","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma.","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"coi250042r14","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma.","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"coi250042r15","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.annonc.2023.09.3108","article-title":"Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study.","volume":"35","author":"Yan","year":"2024","journal-title":"Ann Oncol"},{"issue":"8","key":"coi250042r16","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/S1470-2045(23)00276-0","article-title":"Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial.","volume":"24","author":"Albiges","year":"2023","journal-title":"Lancet Oncol"},{"issue":"21","key":"coi250042r17","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/JCO.21.01944","article-title":"Phase II trial of cabozantinib plus nivolumab in patients with non-clear-cell renal cell carcinoma and genomic correlates.","volume":"40","author":"Lee","year":"2022","journal-title":"J Clin Oncol"},{"issue":"9","key":"coi250042r18","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1200\/JCO.20.02365","article-title":"Open-label, single-arm, phase II study of pembrolizumab monotherapy as first-line therapy in patients with advanced non-clear cell renal cell carcinoma.","volume":"39","author":"McDermott","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"coi250042r19","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003844","article-title":"Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b\/4 CheckMate 920 trial.","volume":"10","author":"Tykodi","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"14","key":"coi250042r20","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1200\/JCO.22.01414","article-title":"Phase II study investigating the safety and efficacy of savolitinib and durvalumab in metastatic papillary renal cancer (CALYPSO).","volume":"41","author":"Su\u00e1rez","year":"2023","journal-title":"J Clin Oncol"},{"issue":"3","key":"coi250042r21","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004780","article-title":"Phase II study of nivolumab and salvage nivolumab\/ipilimumab in treatment-na\u00efve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B).","volume":"11","author":"Atkins","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"3","key":"coi250042r22","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s40265-019-1066-z","article-title":"Sintilimab: first global approval.","volume":"79","author":"Hoy","year":"2019","journal-title":"Drugs"},{"issue":"8","key":"coi250042r23","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1080\/19420862.2019.1654303","article-title":"Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit.","volume":"11","author":"Wang","year":"2019","journal-title":"MAbs"},{"issue":"4","key":"coi250042r24","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.jtho.2020.11.026","article-title":"Phase 1b study of sintilimab plus anlotinib as first-line therapy in patients with advanced NSCLC.","volume":"16","author":"Chu","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"16","key":"coi250042r25","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1200\/JCO.21.02091","article-title":"Efficacy and safety of sintilimab plus anlotinib for PD-L1-positive recurrent or metastatic cervical cancer: a multicenter, single-arm, prospective phase II trial.","volume":"40","author":"Xu","year":"2022","journal-title":"J Clin Oncol"},{"key":"coi250042r26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-068714","article-title":"Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial.","volume":"377","author":"Lu","year":"2022","journal-title":"BMJ"},{"issue":"16","key":"coi250042r27","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1007\/s40265-015-0483-x","article-title":"Axitinib: a review in advanced renal cell carcinoma.","volume":"75","author":"Keating","year":"2015","journal-title":"Drugs"},{"issue":"2","key":"coi250042r28","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"9","key":"coi250042r29","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1200\/JCO.2017.75.1644","article-title":"Immune-modified Response Evaluation Criteria in Solid Tumors (imRECIST): refining guidelines to assess the clinical benefit of cancer immunotherapy.","volume":"36","author":"Hodi","year":"2018","journal-title":"J Clin Oncol"},{"issue":"4","key":"coi250042r31","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.eururo.2022.03.006","article-title":"European Association of Urology guidelines on renal cell carcinoma: the 2022 update.","volume":"82","author":"Ljungberg","year":"2022","journal-title":"Eur Urol"},{"issue":"1","key":"coi250042r32","doi-asserted-by":"publisher","first-page":"4","DOI":"10.6004\/jnccn.2024.0008","article-title":"NCCN Guidelines\u00ae Insights: kidney cancer, version 2.2024.","volume":"22","author":"Motzer","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"coi250042r33","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1002\/ijc.34756","article-title":"Advances in non-clear cell renal cell carcinoma management: from heterogeneous biology to treatment options.","volume":"154","author":"Wilson","year":"2024","journal-title":"Int J Cancer"},{"issue":"4","key":"coi250042r34","doi-asserted-by":"publisher","first-page":"e113","DOI":"10.1016\/j.eururo.2022.12.020","article-title":"Improving systemic therapy for fumarate hydratase-deficient renal cell carcinoma.","volume":"83","author":"Carlo","year":"2023","journal-title":"Eur Urol"},{"issue":"12","key":"coi250042r35","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma.","volume":"380","author":"Motzer","year":"2019","journal-title":"N Engl J Med"},{"issue":"14","key":"coi250042r36","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma.","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med"},{"issue":"16","key":"coi250042r37","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.e16534","article-title":"Efficacy and safety of axitinib in combination with sintilimab as neoadjuvant therapy for patients with locally advanced renal cell carcinoma: a phase II clinical study.","volume":"42","author":"Huang","year":"2024","journal-title":"J Clin Oncol"},{"issue":"10","key":"coi250042r38","doi-asserted-by":"publisher","DOI":"10.1016\/j.crmeth.2023.100596","article-title":"Multi-omics indicators of long-term survival benefits after immune checkpoint inhibitor therapy.","volume":"3","author":"Zhao","year":"2023","journal-title":"Cell Rep Methods"},{"issue":"2","key":"coi250042r39","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000374","article-title":"Tumor copy-number alterations predict response to immune-checkpoint-blockade in gastrointestinal cancer.","volume":"8","author":"Lu","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"15","key":"coi250042r40","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1200\/JCO.23.00225","article-title":"Irreconcilable differences: the divorce between response rates, progression-free survival, and overall survival.","volume":"41","author":"Merino","year":"2023","journal-title":"J Clin Oncol"},{"key":"coi250042r30","volume-title":"Common Terminology Criteria for Adverse Events (CTCAE)","year":"2017","edition":"5th ed"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2837646\/jamaoncology_zhang_2025_oi_250042_1759848040.10486.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T15:01:31Z","timestamp":1760626891000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2837646"}},"subtitle":["A Phase 2 Nonrandomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2025.2497","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,1]]}}}